TAT-10: Progress Toward an Alternate Method for Production of Ac-225

Kanazawa, Japan (Urotoday.com) Northstar Medical Radioisotopes, LLC is a commercial supplier of  Mo99/Tc99m and is looking at potential procedures for large-scale production of Ac225. After examining several possible production paths, high-energy proton spallation was chosen for Th229 production. A  proof-of-concept experiment was carried out using spare protons from Fermilab’s 8 GeV Booster accelerator. The company envisions banks of redundant Thorium/Actinium generators to reach commercial scale supplies of Ac225.

Presented By: James Harvey from Northstar Medical Radioisotopes, LLC, Madison, WI

Written By: William Carithers, Lawrence Berkeley National Laboratory

at the 10th International Symposium on Targeted Alpha Therapy (TAT-10)  May 31 - June 1, 2017 - Kanazawa, Japan.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.